-
Oppenheimer Reports on Optimer Pharmaceuticals (OPTR)
Friday, May 6, 2011 - 9:25am | 178Oppenheimer released a report on Optimer Pharmaceuticals (NASDAQ: OPTR) earlier today. In the report, Oppenheimer was bullish on the pharmaceutical company. Oppenheimer writes, “OPTR reported 1Q11 EPS of $1.04, above our ($0.36) EPS estimate, driven by a one-time upfront licensing payment from...
-
Benzinga's Top Pre-Market NASDAQ Losers (OMPI, TITN, PCLN, VOD)
Friday, May 6, 2011 - 8:21am | 133Obagi Medical Products Inc (NASDAQ: OMPI) dipped 27.13% to $9.40 in the pre-market session. On a GAAP basis, OMPI reported a Q1 net loss at $2.4 million, versus a net income of $1.9 million, in the year-ago period. Titan Machinery Inc (NASDAQ: TITN) fell 2.23% to $29.77 in the pre-market session....
-
Benzinga's Top Downgrades (PCLN, OMPI, WESTD, PSA)
Friday, May 6, 2011 - 8:20am | 135Goldman Sachs downgraded Priceline.com Inc (NASDAQ: PCLN) from “buy” to “neutral.” PCLN's shares closed at $533.97 yesterday. PCLN's PEG ratio is 1.27. Robert W. Baird downgraded Obagi Medical Products Inc (NASDAQ: OMPI) from “outperform” to “neutral.” OMPI's stock closed at $12.90 yesterday. OMPI...
-
J.P. Morgan Reports Strong 1Q11 For Medicis Pharmaceutical
Friday, May 6, 2011 - 8:01am | 105According to J.P. Morgan, Medicis Pharmaceutical (NYSE: MRX) saw strong 1Q11 results. J.P. Morgan said that while Medicis reported 1Q/11 EPS of $0.50 that was roughly inline with consensus, underlying top line and EPS results were in fact well above expectations as the company recorded one-time...
-
Piper Jaffray Overweight On DURECT Corporation (DRRX)
Friday, May 6, 2011 - 7:50am | 188Piper Jaffray has an Overweight rating and a $4 price target on shares of DURECT Corporation (NASDAQ: DRRX) after it reported earnings. In a note to investors, Piper Jaffray writes, "Last night, DURECT reported a 1Q11 net loss per share of $0.07, in-line with our estimate. Cash on hand totaled $...
-
Piper Jaffray Raises PT On Medicis Pharmaceutical To $44
Friday, May 6, 2011 - 7:41am | 27Piper Jaffray has raised the price target on Medicis Pharmaceutical (NYSE: MRX) from $38 to $44 and maintains its Overweight rating.
-
JP Morgan Raises PT On Medicis Pharmaceutical To $42
Friday, May 6, 2011 - 6:01am | 27JP Morgan has raised the price target on Medicis Pharmaceutical (NYSE: MRX) from $35 to $42 and maintains its Overweight rating.
-
Fast Money Picks For May 6th (JNJ, VALE, AEO, TGT)
Thursday, May 5, 2011 - 8:08pm | 188CNBC Fast Money's Anthony Scaramucci recommended on the show a long position in Johnson & Johnson (NYSE: JNJ). He likes it because it is a defensive name. Johnson & Johnson (JNJ) fell 1.01% today, and it closed at $65.01. Tim Seymour thinks that you should buy Vale (ADR) (NYSE: VALE)...
-
DepoMed Reports EPS of $1.77 vs. $1.05 Estimate; Revenues $83.1M vs. $81.42M Estimate (DEPO)
Thursday, May 5, 2011 - 4:41pm | 21DepoMed (NASDAQ: DEPO) Reports EPS of $1.77 vs. $1.05 Estimate; Revenues $83.1M vs. $81.42M Estimate
-
Salix Pharma Reports Q1 EPS of $0.34 vs. $0.18 Estimate; Revenues $105.9M vs. $107.9M Estimate (SLXP)
Thursday, May 5, 2011 - 4:19pm | 23Salix Pharma (NASDAQ: SLXP) Reports Q1 EPS of $0.34 vs. $0.18 Estimate; Revenues $105.9M vs. $107.9M Estimate.
-
Deutsche Bank Has Buy On XenoPort (XNPT)
Thursday, May 5, 2011 - 9:17am | 189Deutsche Bank has a Buy rating and a $13 price target on shares of XenoPort (NASDAQ: XNPT) following earnings. In a note to investors, Deutsche Bank writes, "In conjunction with the Q1 results, XNPT disclosed a new preclinical compound (XP23829) - an oral prodrug of methyl hydrogenfumarate (MHF)...
-
The European Commission Approves Pfizer's Revatio for the Treatment of Pulmonary Arterial Hypertension in Children
Thursday, May 5, 2011 - 8:25am | 62Pfizer Inc. (NYSE: PFE) announced that Revatio has been approved by the European Commission for the treatment of pediatric patients aged 1 to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in...
-
Par Pharma Reports EPS of $0.96 vs. $0.89 Estimate; Revenues $233.0M vs. $227.77M Estimate
Thursday, May 5, 2011 - 7:35am | 22Par Pharma (NYSE: PRX) Reports EPS of $0.96 vs. $0.89 Estimate; Revenues $233.0M vs. $227.77M Estimate
-
Mylan Launches Generic Version of Percodan Tablets
Thursday, May 5, 2011 - 7:33am | 56Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Oxycodone and Aspirin Tablets USP, 4.8355 mg/325 mg, based on an agreement with licensing partner Coastal Pharmaceuticals. This product is the generic version of Endo Pharmaceuticals' Percodan®...
-
J.P. Morgan Maintain Neutral Rating But Increases Price Target On Allergan To $83.00 From $80.00 (AGN)
Thursday, May 5, 2011 - 7:24am | 97According to J.P. Morgan, after strong 1Q results, they are raising the price target on Allergan (NYSE: AGN) to $83.00 from $80.00 and are maintaining the neutral rating. In the report, J.P. Morgan said, "Allergan reported solid 1Q/11 results (+$0.03 EPS beat despite higher than expected SG&A...